ANI Pharmaceuticals reports Q4 non-GAAP EPS 76c, consensus 67c

Reports Q4 revenue $94.2M, consensus $86.14M. "2022 was a transformative year for ANI, taking us past critical inflection points for our two key growth drivers – the launch of Cortrophin Gel, our foundational Rare Disease asset, and investment in our generics business. Over the course of the past year, we built a strong Rare Disease platform to support Cortrophin Gel, which also creates the opportunity to acquire or partner on additional rare disease assets that can leverage this foundation. In addition, our continued focus on bringing limited-competition products to market, driving cost competitiveness and providing supply reliability has helped us absorb the generic product erosion and deliver results," stated Nikhil Lalwani, CEO. "ANI’s full-year 2022 revenues of $316.4M marked a milestone achievement for the Company and reflects the dedication and commitment of our colleagues. As we look ahead to 2023, we will continue to focus on providing high-quality medicines to patients in need and to deliver value to all stakeholders," concluded Lalwani.